Condition
Hilar Cholangiocarcinoma clinical trials and research
Research outlook What's coming for Cholangiocarcinoma: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 4 Hilar Cholangiocarcinoma clinical trials that are recruiting, at sites in 3 countries (most in China (2), Netherlands (1), Germany (1)). By phase: Phase 4 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest Hilar Cholangiocarcinoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Blood test using cfDNA methylation to screen for biliary tract cancers | — | Shanghai, Shanghai Municipality | Recruiting | Sep 16, 2025 |
| Preoperative Lymph Node Assessment in Cholangiocarcinoma using Endoscopic Ultrasound | — | Rotterdam, South Holland and 5 other locations | Recruiting | Sep 9, 2025 |
| Neoadjuvant tislelizumab with SBRT and gemcitabine/platinum chemotherapy for borderline or unresectable hilar bile duct cancer | Phase 2 | Jinan, Shandong | Recruiting | Jun 22, 2025 |
| Comparing two treatments for non-resectable bile duct cancer | Phase 4 | Aachen and 19 other locations | Recruiting | Sep 22, 2022 |
All recruiting trials (4)
-
Blood test using cfDNA methylation to screen for biliary tract cancers
This study tests whether a blood test that reads cfDNA methylation can detect biliary tract cancers early in adults with or suspected of having these cancers.
-
Preoperative Lymph Node Assessment in Cholangiocarcinoma using Endoscopic Ultrasound
This study tests how well preoperative endoscopic ultrasound (EUS) finds lymph node metastases in adults with presumed resectable or certain unresectable cholangiocarcinomas to see if surgery should proceed.
-
Neoadjuvant tislelizumab with SBRT and gemcitabine/platinum chemotherapy for borderline or unresectable hilar bile duct cancer
This trial will see if precise radiotherapy (SBRT) followed by the PD‑1 drug tislelizumab plus gemcitabine and platinum chemotherapy can shrink tumors enough to allow surgery and improve survival in people with borderline resectable or unresectable hilar cholangiocarcinoma.
-
Comparing two treatments for non-resectable bile duct cancer
This study is testing whether a light-based treatment or a heat-based treatment works better for people with a type of bile duct cancer that can't be surgically removed.
Related topics
Quick answers
How many Hilar Cholangiocarcinoma clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in China (2 trials), Netherlands (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.